Drug Profile
Research programme: viral fusion protein inhibitors - Fuzians Biomedicals
Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator University of Alabama at Birmingham
- Developer Fuzians Biomedicals
- Class Antiretrovirals; Antivirals; Small molecules
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C; HIV infections; Influenza virus infections
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Hepatitis C in Hong Kong (unspecified route) (Fuzians Biomedicals website, September 2023)
- 11 Sep 2023 Discontinued - Preclinical for HIV infections in Hong Kong (unspecified route) (Fuzians Biomedicals website, September 2023)
- 11 Sep 2023 Discontinued - Preclinical for Influenza virus infections in Hong Kong (unspecified route) (Fuzians Biomedicals website, September 2023)